Physician profile
Emily Cooper
NPI 1003182650
$1,920.44
in general payments reported to CMS, 2019-2025
26 companies · $46.28 in 2025
The $46.28 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $552 · 2021: $222 · 2022: $285 · 2023: $181 · 2024: $139 · 2025: $46.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $425.64 | 2019-2022 | |
| Abbvie INC. | $195.88 | 2020-2024 | Vraylar |
| Amgen INC. | $180.58 | 2019-2024 | Evenity, Prolia |
| Novo Nordisk INC | $164.98 | 2019-2024 | Ozempic, Rybelsus |
| Organogenesis INC. | $136.93 | 2020-2025 | Apligraf, Puraply |
| Glaxosmithkline, LLC. | $135.82 | 2019-2022 | |
| Pfizer INC. | $124.02 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $89.40 | 2019-2022 | |
| Lilly USA, LLC | $81.17 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $48.14 | 2019 | |
| Smith+Nephew, INC. | $47.02 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $32.73 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.10 | 2020-2022 | |
| Abbott Laboratories | $29.31 | 2019-2020 | |
| Tactile Systems Technology INC | $25.11 | 2024 | Entre Plus, Flexitouch Plus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $22.46 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.34 | 2021 | |
| Amarin Pharma, INC. | $17.40 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.28 | 2021 | |
| Exact Sciences Corporation | $14.43 | 2025 | The Cologuard Plus Collection Kit |
| Allergan, INC. | $14.29 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.96 | 2021 | |
| Astellas Pharma US INC | $13.12 | 2023 | Veozah |
| Eisai INC. | $12.52 | 2020 | |
| Organon LLC | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.